273 related articles for article (PubMed ID: 35039873)
1. A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy.
Nonaka W; Takata T; Iwama H; Komatsubara S; Kobara H; Kamada M; Deguchi K; Touge T; Miyamoto O; Nakamura T; Itano T; Masaki T
Mol Med Rep; 2022 Mar; 25(3):. PubMed ID: 35039873
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.
Schirinzi T; Sancesario GM; Di Lazzaro G; Scalise S; Colona VL; Imbriani P; Mercuri NB; Bernardini S; Lang AE; Pisani A
J Neural Transm (Vienna); 2018 Sep; 125(9):1373-1379. PubMed ID: 29948175
[TBL] [Abstract][Full Text] [Related]
3. Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid.
Boman A; Svensson S; Boxer A; Rojas JC; Seeley WW; Karydas A; Miller B; Kågedal K; Svenningsson P
J Parkinsons Dis; 2016 Apr; 6(2):307-15. PubMed ID: 27061067
[TBL] [Abstract][Full Text] [Related]
4. Exosomal miRNA as peripheral biomarkers in Parkinson's disease and progressive supranuclear palsy: A pilot study.
Manna I; Quattrone A; De Benedittis S; Vescio B; Iaccino E; Quattrone A
Parkinsonism Relat Disord; 2021 Dec; 93():77-84. PubMed ID: 34839044
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA as Candidate Biomarkers in Atypical Parkinsonian Syndromes: Systematic Literature Review.
Bougea A
Medicina (Kaunas); 2022 Mar; 58(4):. PubMed ID: 35454322
[No Abstract] [Full Text] [Related]
6. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.
Litvan I; Mangone CA; McKee A; Verny M; Parsa A; Jellinger K; D'Olhaberriague L; Chaudhuri KR; Pearce RK
J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):615-20. PubMed ID: 8648326
[TBL] [Abstract][Full Text] [Related]
7. The phenotypic spectrum of progressive supranuclear palsy.
Respondek G; Höglinger GU
Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1():S34-6. PubMed ID: 26421392
[TBL] [Abstract][Full Text] [Related]
8. Progressive supranuclear palsy: what do we know about it?
Long L; Cai XD; Wei XB; Liao JC; Xu YQ; Gao HM; Chen XH; Wang Q
Curr Med Chem; 2015; 22(10):1182-93. PubMed ID: 25732053
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism.
Williams DR; de Silva R; Paviour DC; Pittman A; Watt HC; Kilford L; Holton JL; Revesz T; Lees AJ
Brain; 2005 Jun; 128(Pt 6):1247-58. PubMed ID: 15788542
[TBL] [Abstract][Full Text] [Related]
10. Progressive supranuclear palsy as differential diagnosis of Parkinson's disease in the elderly.
Fernández-Ferreira R; García-Santos RA; Rodríguez-Violante M; López-Martínez C; Becerra-Laparra IK; Torres-Pérez ME
Rev Esp Geriatr Gerontol; 2019; 54(5):251-256. PubMed ID: 31324404
[TBL] [Abstract][Full Text] [Related]
11. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study.
Litvan I; Campbell G; Mangone CA; Verny M; McKee A; Chaudhuri KR; Jellinger K; Pearce RK; D'Olhaberriague L
Brain; 1997 Jan; 120 ( Pt 1)():65-74. PubMed ID: 9055798
[TBL] [Abstract][Full Text] [Related]
12. The diagnosis of progressive supranuclear palsy: current opinions and challenges.
Ali F; Josephs K
Expert Rev Neurother; 2018 Jul; 18(7):603-616. PubMed ID: 29902389
[TBL] [Abstract][Full Text] [Related]
13. Circulating miRNAs in progressive supranuclear palsy: Recent evidence and future challenges.
Manna I; De Benedittis S; Quattrone A
Parkinsonism Relat Disord; 2022 Aug; 101():18-19. PubMed ID: 35753145
[TBL] [Abstract][Full Text] [Related]
14. Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy.
Simoes FA; Joilin G; Peters O; Schneider LS; Priller J; Spruth EJ; Vogt I; Kimmich O; Spottke A; Hoffmann DC; Falkenburger B; Brandt M; Prudlo J; Brockmann K; Fries FL; Rowe JB; Church A; Respondek G; Newbury SF; Leigh PN; Morris HR; Höglinger GU; Hafezparast M
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498882
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid levels of oxidative stress measured using diacron-reactive oxygen metabolites and biological antioxidant potential in patients with Parkinson's disease and progressive supranuclear palsy.
Takahashi K; Iwaoka K; Takahashi K; Suzuki Y; Taguchi K; Yamahara K; Maeda T
Neurosci Lett; 2021 Jul; 757():135975. PubMed ID: 34023404
[TBL] [Abstract][Full Text] [Related]
16. Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia.
Kanazawa M; Tada M; Onodera O; Takahashi H; Nishizawa M; Shimohata T
Parkinsonism Relat Disord; 2013 Dec; 19(12):1149-51. PubMed ID: 23916652
[TBL] [Abstract][Full Text] [Related]
17. Progressive supranuclear palsy.
Giagkou N; Höglinger GU; Stamelou M
Int Rev Neurobiol; 2019; 149():49-86. PubMed ID: 31779824
[TBL] [Abstract][Full Text] [Related]
18. In vivo comparison of Richardson's syndrome and progressive supranuclear palsy-parkinsonism.
Srulijes K; Mallien G; Bauer S; Dietzel E; Gröger A; Ebersbach G; Berg D; Maetzler W
J Neural Transm (Vienna); 2011 Aug; 118(8):1191-7. PubMed ID: 21207078
[TBL] [Abstract][Full Text] [Related]
19. microRNA profiling: increased expression of miR-147a and miR-518e in progressive supranuclear palsy (PSP).
Tatura R; Buchholz M; Dickson DW; van Swieten J; McLean C; Höglinger G; Müller U
Neurogenetics; 2016 Jul; 17(3):165-71. PubMed ID: 27052995
[TBL] [Abstract][Full Text] [Related]
20. CSF Proteomics in Patients With Progressive Supranuclear Palsy.
Wise A; Li J; Yamakawa M; Loureiro J; Peterson B; Worringer K; Sivasankaran R; Palma JA; Mitic L; Heuer HW; Lario-Lago A; Staffaroni AM; Clark A; Taylor J; Ljubenkov PA; Vandevrede L; Grinberg LT; Spina S; Seeley WW; Miller BL; Boeve BF; Dickerson BC; Grossman M; Litvan I; Pantelyat A; Tartaglia MC; Zhang Z; Wills AA; Rexach J; Rojas JC; Boxer AL;
Neurology; 2024 Aug; 103(3):e209585. PubMed ID: 38959435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
